




# 本邦におけるゲフィチニブ第Ⅰ相試験奏効例一覧

Table 3. Demographics for the 5 patients experiencing partial responses

ZD1839 (mg/day)	Sex	Age (yrs)	Tumor	Previous treatment (month)	ZD1839 treatment cycles	Partial response duration (months)
225	F	51	NSCLC (adenocarcinoma)	cisplatin + docetaxel (2) cisplatin + etoposide (1) cyclophosphamide + etoposide + tegafur-uracil (1.5)	5	4
400	F	63	NSCLC (adenocarcinoma)	bleomycin (1) cisplatin + etoposide (1) etoposide (1)	13	11
525	F	70	NSCLC (adenocarcinoma)	cisplatin + etoposide (3) docetaxel (5)	2	1
525	F	68	NSCLC (adenocarcinoma)	vindesine + mitomycin C + cisplatin (10) docetaxel (2)	13 <sup>a</sup>	11 <sup>a</sup>
700	M	67	NSCLC (adenocarcinoma)	Irinotecan + docetaxel (3)	12 <sup>a</sup>	10 <sup>a</sup>

<sup>a</sup>still dosing

文献11、ASCO 2001から



引紙 3 (文部大 12)

「癌と化学療法」  
Vol. 31, No. 4, 2004年  
567~573

図 1 用量、性別および組織型別の生存曲線

a: 生存期間に及ぼす影響 (用量別、日本人)


b: 生存期間に及ぼす影響 (性別、日本人)

c: 生存期間に及ぼす影響 (組織型、日本人)


\*ITT (intension to treat) 解析 (250 mg 群+500 mg 群)

# Survival after second-line setting gefitinib in patients with metastatic NSCLC (n=1055)


all patients




Histologic type




smoking



gender



ECOG PS




hypoxia



文献13、ASCO 2004から

# Survival after first-line setting gefitinib in patients with metastatic NSCLC (n=254)



文献13、ASCO 2004から

## Multivariate analysis of factors predicting survival after start of gefitinib treatment (Cox model)

Variable	Hazard ratio	95%CI	P value
Male sex	1.66	1.37-2.02	<0.001
Metastatic disease	1.62	1.37-1.91	<0.001
PS 2-4	2.73	2.36-3.15	<0.001
Adenocarcinoma	0.68	0.58-0.79	<0.001
Hypoxia*	1.19	1.10-1.30	<0.001
Current/former smoker	1.43	1.20-1.70	<0.001

\*NCI-CTC version II > Grade 1

N = 1550; median survival time = 317 days; censored cases = 582

文献13、ASCO 2004から